SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) — First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
